Metubine iodide en es it fr

Metubine iodide Brand names, Metubine iodide Analogs

Metubine iodide Brand Names Mixture

  • No information avaliable

Metubine iodide Chemical_Formula


Metubine iodide RX_link

Metubine iodide fda sheet

Metubine_iodide FDA

Metubine iodide msds (material safety sheet)

Metubine iodide Synthesis Reference

No information avaliable

Metubine iodide Molecular Weight

469.955 g/mol

Metubine iodide Melting Point

No information avaliable

Metubine iodide H2O Solubility

Slightly soluble (43 mg/mL at pH 7.4)

Metubine iodide State


Metubine iodide LogP


Metubine iodide Dosage Forms

Capsule (250mg); Tablet (500 mg); Powder for solution (200 mg/mL constituted)

Metubine iodide Indication

For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids.

Metubine iodide Pharmacology

Mycophenolate mofetil is a prodrug of mycophenolic acid, an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.

Metubine iodide Absorption

Rapidly absorbed following oral administration. In 12 healthy volunteers, the mean absolute bioavailability of oral mycophenolate mofetil relative to intravenous mycophenolate mofetil (based on MPA AUC) was 94%. Food (27 g fat, 650 calories) has no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil.

Metubine iodide side effects and Toxicity

Oral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.

Metubine iodide Patient Information

No information avaliable

Metubine iodide Organisms Affected

Humans and other mammals